followed by the one with the largest PRIMARYID value for reports with the same CASEID and FDA_DT
Care 47 , 18731888 (2024)
Testing at 0.63 ATA demonstrated a statistically significant reduction in cognition in the TBI group compared to the matched controls, and this value was equivalent to acutely concussed patients
The company also reported adjusted EBITDA of $82.2 million in the second quarter compared to $39.3 million for the same period in 2024
Lets take a closer look at the pricing details: $15 for 30 patches ($0.50 per patch) Buy 3, pay for 2 deal available 10% off your first order with email sign-up 15% off for subscriptions Additional details: Ships within 7 business days (standard shipping) 30-day return policy, but customer pays return shipping The price is appealing, but theres no licensed provider, no lab monitoring, and no published data showing this method leads to sustained results
Oxidative stress in the pathogenesis and evolution of chronic kidney disease: untangling ariadnes thread